Expansion plans?

Quote












* #109 *
Yesterday, 03:12 AM
Anonymous
*
Posts: n/a
Re: Latuda firings...
Odonnel is only out for himself. He does love the hot girls tho. Watch that guy gaze at every short skirt, tight outfits, revealing cleavage. He can't get enough of it. It's pretty nauseating. Any women reading this knows that what I'm saying is the truth. He's a dog.
 






Anonymous said:
* #109 *
Yesterday, 03:12 AM
Anonymous
*
Posts: n/a
Re: Latuda firings...
Odonnel is only out for himself. He does love the hot girls tho. Watch that guy gaze at every short skirt, tight outfits, revealing cleavage. He can't get enough of it. It's pretty nauseating. Any women reading this knows that what I'm saying is the truth. He's a dog.
Click to expand...

Watch out people. The guy above was fired from Sunovion and has the hots for MO. Obviously upset that MO prefers females. Hope that helps.
 










































I seriously doubt it could be worse than the Otsuka and Lundbeck management of Abilify Maintena. I can't wait til Alkermes starts hiring reps. There are plenty of us waiting to post for these positions.
 












these hirings are being delayed because of the potential lawsuit with otsuka over the citizens petition. i read it and it seems valid but i am no attorney. rumor among many is this will delay the hiring of the field until we here from the fda. snails pace with the fda so concern is this could delay us anywhere from 6 months to 2 years! google the petition-mostly 18 pages of legal jargon but its clear to anyone with half a brain. disappointing
but we shall see.
 












Anonymous said:
these hirings are being delayed because of the potential lawsuit with otsuka over the citizens petition. i read it and it seems valid but i am no attorney. rumor among many is this will delay the hiring of the field until we here from the fda. snails pace with the fda so concern is this could delay us anywhere from 6 months to 2 years! google the petition-mostly 18 pages of legal jargon but its clear to anyone with half a brain. disappointing
but we shall see.
Click to expand...

What are you talking about?
 






Otsuka Tries To Halt Alkermes Ride On Abilify’s Coattails

By Brenda Sandburg
Article # 14140912005
Posted: September 12 2014 6:00 PM

Executive Summary

FDA should not review or approve Alkermes’ NDA for aripiprazole lauroxil because it is based on only one adequate and well-controlled clinical trial, Otsuka argues.
 


















Alkermes Plc (NASDAQ:ALKS) CFO James M. Frates sold 16,000 shares of Alkermes Plc stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $45.29, for a total value of $724,640.00. Following the completion of the transaction, the chief financial officer now directly owns 44,225 shares in the company, valued at approximately $2,002,950. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
 






10/13/2014 10:16 AM ET
Alkermes plc (ALKS: Quote) has been declining for the majority of early trade Monday. The stock is now down 1.14 at $39.10.

Alkermes has been losing ground for the past 3 weeks and has dropped to nearly a 10-month low this morning.
 






Top Bottom
Back
Quote